PhD in Oncology Researcher
Development of radioimmunoconjugates for diagnosis of pancreatic ductal adenocarcinoma.
Molecular imaging of pancreatic ductal adenocarcinoma
Early diagnosis of pancreatic ductal adenocarcinoma (PDAC) remains unmet until today. Over 80% of the patients present with late-stage unresectable tumours that are also resistant to conventional therapies. PDAC tumours currently present the highest fatality rates among solid malignancies, with a 5-year survival rate of less than 5%. My project is focusing on developing a monoclonal antibody and peptide-based molecular imaging agents to allow for early detection of carcinoma in situ lesions among PDAC high-risk populations. Early detection would provide for timely therapeutic intervention, which will improve the current grim statistics.
Prior to starting my PhD in Oncology at Oxford, I graduated from University College London with an MSc in Cancer. I also hold a B. Tech Industrial Microbiology and Biotechnology from the Technical University of Mombasa, Kenya. In 2018, I co-founded the Integrated Cancer Research Foundation of Kenya, a charitable medical research company whose core aims are cutting-edge oncology research, evidence-based cancer education and improvement of access to quality cancer care. I am the current CEO, where I oversee its overall leadership. I am also passionate about helping Africa to have access to safe, effective and affordable cancer therapeutics through the establishment of biopharmaceutical startups.
At free time I love mentoring the youths and leading people to address societal challenges, reading non-fiction books and doing body workouts. I am also a proud dad to Charlene and Graham.
"I am always committed to the course of saving and transforming lives, and helping human to get along with fellow human."